Abstract Background and Aims Matrix metalloproteinase-9 (MMP9) is implicated in the pathogenesis of Crohn’s disease and may serve as a potential biomarker. A phase 2 trial was conducted to examine the efficacy and safety of the anti-MMP9 antibody, andecaliximab (GS-5745), in patients with moderately to severely active Crohn’s disease. Methods Patients were randomized 1:2:2:2 to receive subcutaneous injections of placebo weekly (QW), andecaliximab 150 mg every 2 weeks (Q2W), andecaliximab 150 mg QW, or andecaliximab 300 mg QW. The coprimary study efficacy endpoints were evaluation of a clinical response, defined as liquid or very soft stool frequency and abdominal pain composite (from Patient-Reported Outcome 2) score ≤8 at week 8, and an endoscopic response, defined as a ≥50% reduction from baseline in the Simple Endoscopic Score for Crohn’s Disease, following 8 weeks of treatment. Results A total of 187 participants were randomized to treatment; 53 participants were randomized to each andecaliximab treatment group and 23 participants were randomized to placebo. Proportions of patients receiving andecaliximab were not different from proportions of patients receiving placebo based on clinical and endoscopic response and Crohn’s disease activity index defined remission at week 8. Rates of adverse events were comparable among andecaliximab and placebo. Conclusions Eight weeks of induction treatment with 150 mg andecaliximab Q2W, 150 mg andecaliximab QW, or 300 mg andecaliximab QW in patients with Crohn’s disease did not induce a clinically meaningful symptomatic or endoscopic response. Andecaliximab was well tolerated. Clinical trial registration ClinicalTrials.gov NCT02405442. Crohn’s disease, inflammation, matrix metalloproteinase-9 Copyright © 2018 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: email@example.com This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/about_us/legal/notices)
Journal of Crohn's and Colitis – Oxford University Press
Published: May 29, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera